Adam J Claessens1, Catherine K Yeung2, Linda J Risler1, Brian R Phillips1, Jonathan Himmelfarb3, Danny D Shen4. 1. Pharmacokinetics Laboratory, Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA. 2. Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA Kidney Research Institute, Division of Nephrology, Department of Medicine, School of Medicine, University of Washington, Seattle, WA, USA. 3. Kidney Research Institute, Division of Nephrology, Department of Medicine, School of Medicine, University of Washington, Seattle, WA, USA. 4. Pharmacokinetics Laboratory, Department of Pharmaceutics, School of Pharmacy, University of Washington, Seattle, WA, USA Department of Pharmacy, School of Pharmacy, University of Washington, Seattle, WA, USA Division of Clinical Research, Fred Hutchinson Cancer Research Center, Seattle, WA, USA ds@uw.edu.
Abstract
BACKGROUND: Coenzyme Q10 is an endogenous antioxidant as well as a popular dietary supplement. In blood circulation, coenzyme Q10 exists predominantly as its reduced ubiquinol-10 form, which readily oxidizes to ubiquinone-10 ex vivo. Plasma concentrations of coenzyme Q10 reflect net overall metabolic demand, and the ratio of ubiquinol-10:ubiquinone-10 has been established as an important biomarker for oxidative stress. However, the lability of ubiquinol-10 makes accurate determination of both forms of coenzyme Q10 difficult. Ex vivo oxidation of ubiquinol-10 to ubiquinone-10 during sample collection, processing and analysis may obfuscate the in vivo ratio. METHODS: We developed a rapid and sensitive method for the determination of ubiquinol-10 and ubiquinone-10 in human plasma, using coenzyme Q9 analogues as internal standards. Single-step protein precipitation in 1-propanol, a lipophilic and water-soluble alcohol, allowed for rapid extraction. RESULTS: Analysis by ultra performance liquid chromatography-tandem mass spectrometry provided rapid run-time and high sensitivity, with lower limits of quantitation for ubiquinol-10 and ubiquinone-10 of 5 μg/L and 10 μg/L, respectively. CONCLUSIONS: This method is suitable for clinical studies with coenzyme Q10 supplementation in various disease states where this lipid-antioxidant may be beneficial. We have applied this method to >300 plasma samples from coenzyme Q10 research studies in chronic haemodialysis patients and postsurgical patients.
BACKGROUND: Coenzyme Q10 is an endogenous antioxidant as well as a popular dietary supplement. In blood circulation, coenzyme Q10 exists predominantly as its reduced ubiquinol-10 form, which readily oxidizes to ubiquinone-10 ex vivo. Plasma concentrations of coenzyme Q10 reflect net overall metabolic demand, and the ratio of ubiquinol-10:ubiquinone-10 has been established as an important biomarker for oxidative stress. However, the lability of ubiquinol-10 makes accurate determination of both forms of coenzyme Q10 difficult. Ex vivo oxidation of ubiquinol-10 to ubiquinone-10 during sample collection, processing and analysis may obfuscate the in vivo ratio. METHODS: We developed a rapid and sensitive method for the determination of ubiquinol-10 and ubiquinone-10 in human plasma, using coenzyme Q9 analogues as internal standards. Single-step protein precipitation in 1-propanol, a lipophilic and water-soluble alcohol, allowed for rapid extraction. RESULTS: Analysis by ultra performance liquid chromatography-tandem mass spectrometry provided rapid run-time and high sensitivity, with lower limits of quantitation for ubiquinol-10 and ubiquinone-10 of 5 μg/L and 10 μg/L, respectively. CONCLUSIONS: This method is suitable for clinical studies with coenzyme Q10 supplementation in various disease states where this lipid-antioxidant may be beneficial. We have applied this method to >300 plasma samples from coenzyme Q10 research studies in chronic haemodialysis patients and postsurgical patients.
Authors: Lili Miles; Michael V Miles; Peter H Tang; Paul S Horn; John G Quinlan; Brenda Wong; Alexandra Wenisch; Kevin E Bove Journal: Clin Chim Acta Date: 2005-10 Impact factor: 3.786
Authors: Michael V Miles; Bonnie J Patterson; Melinda L Chalfonte-Evans; Paul S Horn; Francis J Hickey; Mark B Schapiro; Paul E Steele; Peter H Tang; Stephanie L Hotze Journal: Pediatr Neurol Date: 2007-12 Impact factor: 3.372
Authors: Matthew B Rivara; Catherine K Yeung; Cassianne Robinson-Cohen; Brian R Phillips; John Ruzinski; Denise Rock; Lori Linke; Danny D Shen; T Alp Ikizler; Jonathan Himmelfarb Journal: Am J Kidney Dis Date: 2016-12-04 Impact factor: 8.860
Authors: Nils Burger; Angela Logan; Tracy A Prime; Amin Mottahedin; Stuart T Caldwell; Thomas Krieg; Richard C Hartley; Andrew M James; Michael P Murphy Journal: Free Radic Biol Med Date: 2019-12-05 Impact factor: 7.376
Authors: Catherine K Yeung; Frederic T Billings; Adam J Claessens; Baback Roshanravan; Lori Linke; Mary B Sundell; Suhail Ahmad; Baohai Shao; Danny D Shen; T Alp Ikizler; Jonathan Himmelfarb Journal: BMC Nephrol Date: 2015-11-03 Impact factor: 2.388